US Stocks Edge Higher; Goldman Sachs Downgrades Tesla To Neutral
Portfolio Pulse from Lisa Levin
US stocks edged higher with the Dow Jones gaining around 25 points on Monday. Goldman Sachs downgraded Tesla to Neutral, while raising the price target from $185 to $248. Tesla received back-to-back downgrades last week from Barclays and Morgan Stanley. TRxADE HEALTH, MoonLake Immunotherapeutics, and Acelyrin saw significant gains, while Avalo Therapeutics, FibroGen, and Nauticus Robotics experienced declines.
June 26, 2023 | 1:44 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Avalo Therapeutics shares dropped 84% to $0.70 after the company's Phase 2 Peak trial for quisovalimab in patients with non-eosinophilic asthma missed its primary endpoint.
The failure of Avalo Therapeutics' Phase 2 Peak trial to meet its primary endpoint has led to a significant decline in the company's stock price, indicating negative investor sentiment and potential for further short-term losses.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
FibroGen shares were down 79% to $3.32 after the company's Phase 3 ZEPHYRUS-1 trial of pamrevlumab failed to meet its primary endpoint in idiopathic pulmonary fibrosis patients.
The failure of FibroGen's Phase 3 ZEPHYRUS-1 trial to meet its primary endpoint has led to a significant decline in the company's stock price, indicating negative investor sentiment and potential for further short-term losses.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Nauticus Robotics shares were down 15% to $1.96 after the company announced its inclusion in the Russell Microcap Index.
The inclusion of Nauticus Robotics in the Russell Microcap Index may have led to increased scrutiny and selling pressure, resulting in a decline in the company's stock price. This could indicate potential for further short-term losses.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100
NEGATIVE IMPACT
Goldman Sachs downgraded Tesla to Neutral and raised the price target from $185 to $248. Tesla received back-to-back downgrades last week from Barclays and Morgan Stanley.
The downgrade from Goldman Sachs, along with the back-to-back downgrades from Barclays and Morgan Stanley last week, could negatively impact Tesla's stock price in the short term as investors may perceive this as a sign of weakening confidence in the company's growth prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
TRxADE HEALTH shares shot up 95% to $16.47 after issuing a correction to a press release announcing its anticipated combination with Superlatus, Inc.
The correction to the press release regarding the anticipated combination with Superlatus, Inc. has led to a significant increase in TRxADE HEALTH's stock price, indicating positive investor sentiment and potential for further short-term gains.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
MoonLake Immunotherapeutics shares shot up 89% to $48.80 after the company's Phase 2 study for Nanobody sonelokimabint met its primary endpoint in hidradenitis suppurativa.
The positive results from MoonLake Immunotherapeutics' Phase 2 study indicate potential for the company's Nanobody sonelokimabint, leading to increased investor confidence and a significant rise in the stock price. This could result in further short-term gains.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100